United States - English - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 750 mg - levofloxacin are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin susceptible staphylococcus  aureus , pseudomonas  aeruginosa , serratia  marcescens , escherichia  coli , klebsiella  pneumoniae , haemophilus  influenzae , or streptococcus  pneumoniae . adjunctive therapy should be used as clinically indicated. where pseudomonas  aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see  clinical  studies  (14.1)] . levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible staphylococcus  aureus , streptococcus  pneumoniae (including multi-drug-resistant streptococcus  pneumoniae [mdrsp]), haemophilus  influenzae , haemophilus  parainfluenzae , klebsie

France - French - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

fresenius kabi france sa - lévofloxacine 5 mg sous forme de : lévofloxacine hémihydratée 5 - solution - 5 mg - pour 1 ml de solution > lévofloxacine 5 mg sous forme de : lévofloxacine hémihydratée 5,125 mg - antibiotique de la famille des quinolones groupe fluoroquinolones - classe pharmacothérapeutique : antibiotique de la famille des quinolones groupe fluoroquinolones, code atc : j01ma12.le nom de votre médicament est levofloxacine kabi 5 mg/ml, solution pour perfusion. levofloxacine kabi contient une substance active appelée la lévofloxacine. elle appartient à un groupe de médicaments appelés antibiotiques. la lévofloxacine est un antibiotique de type « quinolone ». elle agit en tuant les bactéries responsables d’infections dans votre organisme.levofloxacine kabi peut être utilisé pour traiter les infections des : poumons, chez les personnes atteintes de pneumonie. voies urinaires, notamment au niveau de vos reins ou votre vessie. prostate, lorsque vous avez une infection qui dure. peau et tissus sous-cutanés, y compris les muscles. c’est ce que l’on appelle parfois les « tissus mous ».dans certaines situations particulières, levofloxacine kabi peut être utilisé pour diminuer les risques de contracter une maladie pulmonaire appelée maladie du charbon ou les risques d’aggravation de la maladie après exposition à la bactérie responsable de la maladie du charbon.

France - French - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

accord healthcare france sas - lévofloxacine 500 mg sous forme de : lévofloxacine hémihydratée 512 - comprimé - 500 mg - pour un comprimé > lévofloxacine 500 mg sous forme de : lévofloxacine hémihydratée 512,46 mg - antibiotiques de la famille des quinolones - classe pharmacothérapeutique : antibiotiques de la famille des quinolones, fluoroquinolones - code atc : j01ma12le nom de votre médicament est levofloxacine accord healthcare 500 mg, comprimé pelliculé sécable. levofloxacine accord healthcare 500 mg, comprimé pelliculé sécable contient une substance active appelée la lévofloxacine. elle appartient à un groupe de médicaments appelés antibiotiques. la lévofloxacine est un antibiotique de type « quinolone ». elle agit en tuant les bactéries responsables d'infections dans votre organisme.levofloxacine accord healthcare 500 mg, comprimé pelliculé sécable peut être utilisé pour traiter les infections des : sinus. poumons, chez les personnes ayant des problèmes respiratoires chroniques ou une pneumonie. voies urinaires, notamment au niveau de vos reins ou votre vessie. prostate, lorsque vous avez une infection qui dure. peau et tissus sous-cutanés, y compris les muscles. c'est ce que l'on appelle parfois les « tissus mous ».dans certaines situations particulières, levofloxacine accord healthcare 500 mg, comprimé pelliculé sécable peut être utilisé pour diminuer les risques de contracter une maladie pulmonaire appelée maladie du charbon ou les risques d'aggravation de la maladie après exposition à la bactérie responsable de la maladie du charbon.

United States - English - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin tablets and other antibacterial drugs, levofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. levofloxacintablets are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. culture and susceptibility testing appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see micr

United States - English - NLM (National Library of Medicine)

wockhardt limited - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin tablets and other antibacterial drugs, levofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. levofloxacin tablets are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. culture and susceptibility testing appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see mic

United States - English - NLM (National Library of Medicine)

proficient rx lp - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 750 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin tabletsand other antibacterial drugs, levofloxacin tabletsshould be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. levofloxacin tablets are indicated for the treatment of adults (≥ 18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. culture and susceptibility testing appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see micr

United States - English - NLM (National Library of Medicine)

proficient rx - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 500 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin tabletsand other antibacterial drugs, levofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. levofloxacin tablets are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. culture and susceptibility testing appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see micr

United States - English - NLM (National Library of Medicine)

wockhardt usa llc. - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin tablets and other antibacterial drugs, levofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. levofloxacin  tablets are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. culture and susceptibility testing appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see mi

United States - English - NLM (National Library of Medicine)

blenheim pharmacal, inc. - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 500 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. levofloxacin tablets are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. culture and susceptibility testing appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see microbiology (12.4

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 250 mg - levofloxacin are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin susceptible staphylococcus   aureus , pseudomonas   aeruginosa , serratia   marcescens , escherichia   coli , klebsiella   pneumoniae , haemophilus   influenzae , or streptococcus   pneumoniae . adjunctive therapy should be used as clinically indicated. where pseudomonas   aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see   clinical   studies   ( 14.1)] . levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible staphylococcus   aureus , streptococcus   pneumoniae (including multi-drug-resistant streptococcus   pneumoniae [mdrsp]), haemophilus   influenzae , haemophilus   parain